Table 3.
Demyelination | |||||||||
---|---|---|---|---|---|---|---|---|---|
Brain | Spinal cord | Optic Nerve | Clinical symptom | ||||||
Treatment | % b | Meanc ± SEM | % b | Meanc ± SEM | % b | Meanc ± SEM | % | Score | Mortality |
PLP | 87 | 194±96 | 50 | 82±64 | 0 | 0 | 0 | 0 | 0 |
PLP+IFN-β DNA | 33 | 5±2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
PLP+HSV-IL-12p70 | 100 | 206±18 | 50 | 85±25 | 0 | 0 | 0 | 0 | 0 |
Mice were immunized with PLP peptide as we described in Materials and methods. Some of the MOG immunized mice were injected with IFN-β DNA, while some mice were ocularly infected with 2X107 PFU/eye of HSV-IL-12p70. The presence of demyelination in ONs, SCs, and brains was assessed on day 29 post treatment. Clinical symptomatology was assessed daily for 29 days or until death.
Percent of mice showing demyelination.
Area of plaque/section ± standard error of mean (SEM) in treated mice.